Elevated Lipoprotein(a) Predicts Recurrent Myocardial Infarction in Diabetic Patients Following Acute Coronary Syndromes.
Ermilo Echeverria-Ortegon, Mario César Torres-Chávez, Alfredo Pérez-Tagle Tejeda et al.
✦ AI-curated · Sources linked
In 30 seconds
This PRISMA-guided systematic review and meta-analysis assessed whether elevated lipoprotein(a) predicts recurrent events in patients with diabetes after acute coronary syndrome or percutaneous coronary intervention. Seven observational studies included 7887 patients. Elevated lipoprotein(a) was associated with recurrent myocardial infarction (pooled HR 2.17, 95% CI 1.02-4.62), but not with repeat coronary revascularization (pooled HR 1.68, 95% CI 0.79-3.57). The findings suggest a possible role for lipoprotein(a) in residual risk after these events, while the observational evidence and substantial heterogeneity warrant caution.
Key findings
- Elevated lipoprotein(a) was associated with recurrent MI: pooled HR 2.17, 95% CI 1.02-4.62; I 2 = 75%.
- No statistically clear association was found with repeat coronary revascularization: pooled HR 1.68, 95% CI 0.79-3.57; I 2 = 78%.
- The meta-analysis included seven observational studies comprising 7887 patients with diabetes and prior ACS or PCI.
Why it matters
Recurrent ischemic events remain a concern in patients with diabetes after ACS or PCI. The association between elevated lipoprotein(a) and recurrent MI identifies a potential marker of residual cardiovascular risk in this population. The absence of a clear association with repeat revascularization and the heterogeneity across studies mean the results should be interpreted as prognostic evidence, not proof of causation.
What to keep in mind
The evidence came from observational studies, with substantial heterogeneity and limited evidence for repeat revascularization.